Related Experiment Video
Updated: May 19, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
Interferon-free hepatitis C therapy: how close are we?
1Division of Gastroenterology/Hepatology and Liver Disease Center, Scripps Clinic, The Scripps Translational Science Institute and The Scripps Research Institute, La Jolla, CA 92037, USA. pockros.paul@scrippshealth.org
Abstract:
Two oral direct-acting antivirals (DAA) are now available for the treatment of chronic hepatitis C infection and several generations of DAA are in development. Expectations are that, at some time in the near future, hepatitis C will be 'curable' with an all-oral DAA regimen. This article reviews the current problems associated with interferon-based hepatitis C treatments that are combined with DAAs, including adverse events and complications of therapy, contraindications, drug-drug interactions and cost. The article further discusses difficulties with new drug development and provides an opinion on the research issues still to be dealt with and the requirements for the successful implementation of such a strategy. These include lack of efficacy in certain populations, unexpected side effects, antiviral resistance, late relapse, lack of cooperation between drug developers and cost.
More Related Videos
06:28Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus
Published on: October 1, 2015
09:35Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
Published on: February 1, 2017
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Hepatitis
Viral Hepatitis I: Introduction
Retrovirus Life Cycles